Trial Profile
A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Antithymocyte globulin; Ciclosporin; Corticosteroids; Mycophenolate mofetil
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Acronyms SCHEDULE
- Sponsors Novartis Healthcare; Novartis Norge; Novartis Pharmaceuticals
- 06 Apr 2019 Results of the substudy assessing the association between mild ACR within 1 year of heart transplantation and development of CAV at 3 years post heart transplantation, presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 12 Mar 2019 Results published in the Transplantation
- 14 Apr 2018 Results of 3 years follow up assessing the effect of everolimus vs calcineurin inhibitors on left ventricular mass in heart transplant patients presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation